Regeneron and non-U.S. commercialization partner Bayer got some great news last week, when the European Committee for Medicinal Products for Human Use (CHMP) recommended its eye drug Eylea for approval for the treatment of visual impairment due to diabetic macular edema (DME). It's a big potential follow-on indication (as many as 6.2 million people) for a drug that's already been approved and made just under $2 billion in sales last year.
This is a drug that analysts estimate could bring in as much as $4.7 billion annually in peak sales for Regeneron.
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson lay out Regeneron's exciting prospects for this drug.
Leaked: This coming blockbuster will make every biotech -- even Regeneron --jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article Regeneron's $4.7 Billion Opportunity originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.